These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 30942617

  • 1. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G, Banaschewski T, Feldman BL, Gustafsson PA, Murphy B, Reynolds M, Coghill DR, Spalding WM.
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A, Hoo-Cardiel A, Lang P.
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J, Sikirica V, Mathurin K.
    BMC Psychiatry; 2016 Jan 16; 16():11. PubMed ID: 26774811
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep 16; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 8. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
    Suehs BT, Sikirica V, Mudumby P, Dufour R, Patel NC.
    J Manag Care Spec Pharm; 2015 Sep 16; 21(9):793-802, 802a-802i. PubMed ID: 26308226
    [Abstract] [Full Text] [Related]

  • 9. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
    Lachaine J, Ben Amor L, Pringsheim T, Burns J, van Stralen J.
    J Child Adolesc Psychopharmacol; 2019 Dec 16; 29(10):730-739. PubMed ID: 31433205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
    Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S.
    J Atten Disord; 2017 Jan 16; 21(2):110-119. PubMed ID: 24071772
    [Abstract] [Full Text] [Related]

  • 12. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
    McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, Sturm A, Whelan F, Hellemann G, Sugar C, Bilder RM.
    J Am Acad Child Adolesc Psychiatry; 2016 Aug 16; 55(8):657-666.e1. PubMed ID: 27453079
    [Abstract] [Full Text] [Related]

  • 13. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov 16; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 14. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Loe IM, Mittal S, Tulio S, Vanderbilt D, Blum NJ.
    JAMA; 2021 May 25; 325(20):2067-2075. PubMed ID: 33946100
    [Abstract] [Full Text] [Related]

  • 15. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun 25; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 16. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI.
    Curr Med Res Opin; 2018 Apr 25; 34(4):619-632. PubMed ID: 29298540
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec 25; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.